toopersent (< 20)

Biotech News: Generex (GNBT)

August 04, 2009 – Comments (0) | RELATED TICKERS: GNBT

All you biotech spec buffs probably know about GNBT.  They are currently at an interesting and pivotal crossroads in their development as a company.  They WERE a pure R&D firm, researching and developing a platform to deliver drugs orally.  Its technical and I don't even really understand the science behind it.  But they have crossed over and are ready to start growing sales.  They have so much potential, that even Joseph Rubinfeld (co-founder of Amgen) has signed on to be their chief scientific advisor.  Dr. Rubinfeld has a highly distinguished and storied carrer in his field and should be a hugh asset to GNBT in helping to develop their market strategy.   Read the article here.

They are up 13% on the news, at a whopping $.73 per share. 

I do own a modest position in GNBT, and as always I recommend doing your due dilligence before buying any company.